Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.31 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3374281 | 0.83 | BRD4 (0.43) | BRD4GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL13348363 | 0.83 | BRD4 (0.43) | BRD4GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL13348215 | 0.82 | — | — | |
| SCHEMBL13348250 | 0.81 | SMN1; SMN2 (0.48) | — | |
| SCHEMBL13348316 | 0.78 | SMN1; SMN2 (0.38) | — | |
| SCHEMBL13823401 | 0.77 | KMT2A (0.42) | NR4A2 | |
| SCHEMBL10286760 | 0.76 | EGFR (0.35) | — | |
| SCHEMBL13650423 | 0.76 | ALDH1A1 (0.34) | — | |
| SCHEMBL13270509 | 0.75 | ALDH1A1 (0.35) | NR4A2 | |
| SCHEMBL13348246 | 0.74 | PDGFRB (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | BRD4 2556/4885GABRA1 1879/4885GABRG2 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.